Navigation Links
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Date:2/10/2012

SAN DIEGO, Feb. 10, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of transrenal molecular diagnostics, has announced that Stephen Zaniboni has been named Chief Financial Officer.

Mr. Zaniboni's experience includes raising more than $500 million through venture financing and IPO proceeds.  Mr. Zaniboni previously served as Chief Financial Officer of healthcare software solutions company Awarepoint and XIFIN Inc., a provider of revenue cycle management for diagnostic service providers. Mr. Zaniboni has also served as Chief Financial Officer of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Mr. Zaniboni played an important role in the sale of AviaraDx to bioMerieux, which continues to operate the company under the name bioTheranostics. Before AviaraDx, Mr. Zaniboni served as CFO of Arcturus Bioscience Inc., where he played an important role in the sale of Arcturus' life science business assets to Molecular Devices Inc. Prior to Arcturus, from 1997 to 2005; Mr. Zaniboni served as Chief Financial Officer of Sequenom  where he lead the efforts behind a very successful IPO. Mr. Zaniboni is co-founder of Sorrento Therapeutics, Inc. and served as a member of its board of directors until 2011. He was a practicing CPA with Arthur Andersen and holds a B.S. in accounting from Boston University and an M.B.A. from Boston College. 

"I am pleased that Steve joins our team to lead the transition of Trovagene from a research stage organization to a commercial enterprise," states Antonius Schuh, Ph.D.,  Trovagene's Chief Executive Officer. "This transition requires an experienced Chief Financial Officer with a successful track record of raising capital, building organizations and creating value for shareholders. I look forward to working with him again."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the sf3b1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Trovagene has filed a Form 10 with the SEC. More complete current information about Trovagene is contained in the filing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.

Contact

Trovagene, Inc.
Stephen Zaniboni
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com

Venanzio Ciampa
+1 (212) 217 9065
venanzio@thepromofact.com

 


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Call Stephen Michnick a gene grammarian
2. American Society for Microbiology honors J. Stephen Dumler
3. Stephen Maturo, M.D., ear, nose and throat specialist, receives Charles Ferguson Award
4. 2011 Stephen H. Schneider Symposium
5. FSU joins coalition working to improve nations power grid
6. GEN joins Charles Darwin 2009 celebration
7. Genomatix joins Illumina-Connect program
8. Internationally acclaimed researcher joins UH faculty thanks to $5.5 million grant
9. Mycotoxin Research joins Springers life sciences journals program
10. Anatomical Science International joins Springers publishing program
11. DEIMOS joins MARS and its satellite of instruments on seafloor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... A recent ... the most troublesome and difficult to control weed in 12 categories of broadleaf crops, ... Almost 200 weed scientists across the U.S. and Canada participated in the 2016 survey, ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider ... the occasion with a strong presence at Bio-IT World Conference & Expo 2017 ... an invitation to all attendees to view posters on the entire range ...
(Date:5/23/2017)... ... May 22, 2017 , ... A ... in San Diego, California, this August will feature high-level speakers on quantum devices, ... , SPIE Optics and Photonics, the largest multidisciplinary optical sciences meeting in North ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq Technology, a ... a facility expansion to accommodate its rapid growth. , The renovations at the ... renovation of the existing areas. The expansion includes, a state-of-the-art engineering facility, and ...
Breaking Biology Technology: